Rigel Pharmaceuticals Inc
RIGL· Nasdaq
RIGLRigel Pharmaceuticals Inc
Released Mar 2, 2021, after the close
10-K filed Mar 2, 2021, 61 days after period end · 0001558370-21-002254
| Metric | Q4 2020 | Q4 2019 | Q4 2018 | Q4 2017 |
|---|---|---|---|---|
| Revenue | $18.45M | $15.40M | $37.86M | $0.00 |
| Net Income | -$19.24M | -$17.20M | $3.23M | -$25.87M |
| EPS Diluted |
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR
| -$0.11 |
| -$0.10 |
| $0.02 |
| -$0.18 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
